Eiger BioPharmaceuticals, Inc. Forecast, price target & analysts
Eiger BioPharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation
Eiger BioPharmaceuticals, Inc. Classifications & Recommendation:
Eiger BioPharmaceuticals, Inc. Price Target
| Target Price | $30.00 |
| Price | $8.50 |
| Potential |
252.94%
register free of charge
|
| Number of Estimates | 1 |
|
1 Analyst has issued a Eiger BioPharmaceuticals, Inc. price target 2025.
The average Eiger BioPharmaceuticals, Inc. target price is $30.00.
This is
252.94%
register free of charge
|
|
| A rating was issued by 1 analysts: 1 Analysts recommend Eiger BioPharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Eiger BioPharmaceuticals, Inc. stock has an average upside potential 2025 of
252.94%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 15.77 | 25.20 |
| 16.99% | 59.80% | |
| Net Margin | -476.57% | -91.62% |
| 37.76% | 80.77% |
1 Analyst has issued a sales forecast Eiger BioPharmaceuticals, Inc. 2024 . The average Eiger BioPharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Eiger BioPharmaceuticals, Inc. 2024 . The average Eiger BioPharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -50.78 | -15.60 |
| 27.19% | 69.28% | |
| P/E | negative | |
| EV/Sales | 0.39 |
1 Analysts have issued a Eiger BioPharmaceuticals, Inc. forecast for earnings per share. The average Eiger BioPharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Eiger BioPharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Eiger BioPharmaceuticals, Inc....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
